Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation
What is the purpose of this trial?
This study is designed to assess the effectiveness of eculizumab in recipients of kidney transplantation with donor-specific antibodies (DSA) and worsening kidney function and to assess if eculizumab improves endothelial cell injury in the kidney.
The investigators hypothesize that complement inhibition with eculizumab will reduce allograft injury, resulting from less complement-mediated injury of endothelial cells and less endothelial cell activation.
- 18 Years - 65 Years
- Alexion Pharmaceuticals
- March 2011
- Last Updated:
- July 18, 2012
- Study HIC#:
Clinicaltrials.gov ID: NCT01327573